Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men

Chintan V Dave; Sebastian Schneeweiss; Elisabetta Patorno

doi:10.1001/jamainternmed.2019.2813

Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men

JAMA Intern Med. 2019 Nov 1;179(11):1587-1590. doi: 10.1001/jamainternmed.2019.2813.

Authors

Chintan V Dave¹, Sebastian Schneeweiss¹, Elisabetta Patorno¹

Affiliation

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Abstract

This cohort study assesses the association between initiation of sodium-glucose cotransporter 2 (SGLT-2) inhibitor treatment and the risk of hospitalization for Fournier gangrene among men.

Grants and funding

K08 AG055670/AG/NIA NIH HHS/United States